BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma

Reuters14:02

BRIEF-<a href="https://laohu8.com/S/GCVRZ">Sanofi</a> And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma

Dec 23 (Reuters) - Sanofi SA SASY.PA:

SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMA
APPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMONSTRATING DUPIXENT SIGNIFICANTLY REDUCED EXACERBATIONS
DUPIXENT REDUCES ASTHMA EXACERBATIONS BY 54%-65%

Source text: ID:nGNEbs95KF

Further company coverage: SASY.PA

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593461309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 14:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593461309","market":"nz","top_or_hot":-1,"title":"BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma</title></head><body><p><span>Dec 23 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> SA <span>SASY.PA</span>:</p><ul><li><p>SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMA</p></li><li><p>APPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMONSTRATING DUPIXENT SIGNIFICANTLY REDUCED EXACERBATIONS</p></li><li><p>DUPIXENT REDUCES ASTHMA EXACERBATIONS BY 54%-65%</p></li></ul><p>Source text: <span>ID:nGNEbs95KF</span></p><p>Further company coverage: <span>SASY.PA</span></p><p> (Gdansk Newsroom)</p><p> ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 14:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma</title></head><body><p><span>Dec 23 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> SA <span>SASY.PA</span>:</p><ul><li><p>SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMA</p></li><li><p>APPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMONSTRATING DUPIXENT SIGNIFICANTLY REDUCED EXACERBATIONS</p></li><li><p>DUPIXENT REDUCES ASTHMA EXACERBATIONS BY 54%-65%</p></li></ul><p>Source text: <span>ID:nGNEbs95KF</span></p><p>Further company coverage: <span>SASY.PA</span></p><p> (Gdansk Newsroom)</p><p> ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2362540622.SGD","symbol_name":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUA8V1TMS:1","article_id":"2593461309","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593461309","pubTimestamp":1766469777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial AsthmaDec 23 (Reuters) - Sanofi SA SASY.PA:SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0058720904.USD":"联博国际健康护理基金A","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0882574055.USD":"富达全球健康医疗A ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","REGN":"再生元制药公司","BK4588":"碎股","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC"},"translate_title":"简介-赛诺菲和再生元的Dupixent在日本获批用于儿童支气管哮喘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial AsthmaDec 23 (Reuters) - Sanofi SA SASY.PA:SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMAAPPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMONSTRATING DUPIXENT SIGNIFICANTLY REDUCED EXACERBATIONSDUPIXENT REDUCES ASTHMA EXACERBATIONS BY 54%-65%Source text: ID:nGNEbs95KFFurther company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593461309","isCrawlerRequest":true}